Lv1
26 积分 2021-12-20 加入
Three ‘E’ challenges for siRNA drug development
3个月前
已完结
Frameworks for transformational breakthroughs in RNA-based medicines
3个月前
已完结
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
3个月前
已完结
PBPK Modeling of PAXLOVIDTM: Incorporating Rotamer Conversion Kinetics to Advanced Dissolution and Absorption Model
4个月前
已完结
An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
4个月前
已完结
An update on the importance of plasma protein binding in drug discovery and development
4个月前
已完结
In Vitro - in Vivo Extrapolation of Hepatic Clearance in Preclinical Species
4个月前
已完结
Quantitative Translation of Substrate Intrinsic Clearance from Recombinant CYP1A1 to Humans
4个月前
已完结
Evaluation of Prediction Accuracy for Volume of Distribution in Rat and Human Using In Vitro, In Vivo, PBPK and QSAR Methods
4个月前
已完结
Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans
4个月前
已完结
皖公网安备34019202002308
